Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Non-Current Assets (2021 - 2025)

Amylyx Pharmaceuticals has reported Other Non-Current Assets over the past 5 years, most recently at $2.5 million for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $2.5 million for Q4 2025, up 10308.33% from a year ago — trailing twelve months through Dec 2025 was $2.5 million (up 10308.33% YoY), and the annual figure for FY2025 was $2.5 million, up 10308.33%.
  • Other Non-Current Assets for Q4 2025 was $2.5 million at Amylyx Pharmaceuticals, roughly flat from $2.5 million in the prior quarter.
  • Over the last five years, Other Non-Current Assets for AMLX hit a ceiling of $2.5 million in Q3 2025 and a floor of $11000.0 in Q1 2025.
  • Median Other Non-Current Assets over the past 5 years was $466000.0 (2022), compared with a mean of $663687.5.
  • Peak annual rise in Other Non-Current Assets hit 10308.33% in 2025, while the deepest fall reached 97.77% in 2025.
  • Amylyx Pharmaceuticals' Other Non-Current Assets stood at $189000.0 in 2021, then skyrocketed by 146.56% to $466000.0 in 2022, then surged by 50.43% to $701000.0 in 2023, then plummeted by 96.58% to $24000.0 in 2024, then surged by 10308.33% to $2.5 million in 2025.
  • The last three reported values for Other Non-Current Assets were $2.5 million (Q4 2025), $2.5 million (Q3 2025), and $11000.0 (Q1 2025) per Business Quant data.